AU745056B2 - Polymer-modified viruses - Google Patents

Polymer-modified viruses Download PDF

Info

Publication number
AU745056B2
AU745056B2 AU68817/98A AU6881798A AU745056B2 AU 745056 B2 AU745056 B2 AU 745056B2 AU 68817/98 A AU68817/98 A AU 68817/98A AU 6881798 A AU6881798 A AU 6881798A AU 745056 B2 AU745056 B2 AU 745056B2
Authority
AU
Australia
Prior art keywords
virus
polymer
modified
antibody
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68817/98A
Other languages
English (en)
Other versions
AU6881798A (en
Inventor
Christina Delgado
Gillian E. Francis
Catherine R O'riordan
Vincent Parkes
Alan E. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymasc Pharmaceuticals PLC
Genzyme Corp
Original Assignee
Polymasc Pharmaceuticals PLC
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706735.9A external-priority patent/GB9706735D0/en
Priority claimed from GBGB9719625.7A external-priority patent/GB9719625D0/en
Priority claimed from GBGB9722316.8A external-priority patent/GB9722316D0/en
Application filed by Polymasc Pharmaceuticals PLC, Genzyme Corp filed Critical Polymasc Pharmaceuticals PLC
Publication of AU6881798A publication Critical patent/AU6881798A/en
Application granted granted Critical
Publication of AU745056B2 publication Critical patent/AU745056B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AU68817/98A 1997-04-03 1998-04-03 Polymer-modified viruses Ceased AU745056B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9706735.9A GB9706735D0 (en) 1997-04-03 1997-04-03 Particles
GB9706735 1997-04-03
GB9719625 1997-09-15
GBGB9719625.7A GB9719625D0 (en) 1997-09-15 1997-09-15 Particles
GBGB9722316.8A GB9722316D0 (en) 1997-10-22 1997-10-22 Particles
GB9722316 1997-10-22
PCT/US1998/006609 WO1998044143A1 (en) 1997-04-03 1998-04-03 Polymer-modified viruses

Publications (2)

Publication Number Publication Date
AU6881798A AU6881798A (en) 1998-10-22
AU745056B2 true AU745056B2 (en) 2002-03-07

Family

ID=27268802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68817/98A Ceased AU745056B2 (en) 1997-04-03 1998-04-03 Polymer-modified viruses

Country Status (5)

Country Link
EP (1) EP0994959A1 (ja)
JP (1) JP2001521381A (ja)
AU (1) AU745056B2 (ja)
CA (1) CA2285416A1 (ja)
WO (1) WO1998044143A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523054A (ja) * 1998-08-24 2002-07-30 ジェンザイム・コーポレイション ポリマーにより修飾されたアデノウイルスのカチオン性複合体
WO2000043044A1 (en) * 1999-01-19 2000-07-27 The Children's Hospital Of Philadelphia Compositions and methods for controlled delivery of virus vectors
GB9913359D0 (en) * 1999-06-09 1999-08-11 Cancer Res Campaign Tech Polymer modified biological elements
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
CA2384814A1 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
AU2002335667A1 (en) * 2001-08-03 2003-02-17 Board Of Regents, The University Of Texas System Modified reoviral therapy
JP4566129B2 (ja) * 2003-02-17 2010-10-20 扶桑薬品工業株式会社 新規ウイルスベクター
WO2005106046A1 (en) * 2004-05-03 2005-11-10 Stefan Kochanek Modified viral vector particles
US7776322B2 (en) 2004-08-16 2010-08-17 Stefan Kochanek Modified viral vector particles
CA2744959A1 (en) 2008-12-11 2010-06-17 Psioxus Therapeutics Limited Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014874A1 (en) * 1994-11-10 1996-05-23 University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1996021036A2 (en) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014874A1 (en) * 1994-11-10 1996-05-23 University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1996021036A2 (en) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity

Also Published As

Publication number Publication date
WO1998044143A9 (en) 1999-04-22
JP2001521381A (ja) 2001-11-06
AU6881798A (en) 1998-10-22
WO1998044143A1 (en) 1998-10-08
EP0994959A1 (en) 2000-04-26
CA2285416A1 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
US6613563B1 (en) Viral vectors with modified tropism
ES2504165T3 (es) Conjugados de polímeros con antigenicidad disminuida, procedimientos de preparación y usos de los mismos
ES2246533T3 (es) Fibra adenovirica modificada y adenovirus dianas.
AU745056B2 (en) Polymer-modified viruses
JP2003523320A (ja) ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
BG62740B1 (bg) Състав за въвеждане на комплекси на нуклеинови киселини в по-висши еукариотни клетки
US20220372514A1 (en) Viruses with modified capsid proteins
US6569426B2 (en) Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
CA2341516A1 (en) Cationic complexes of polymer-modified adenovirus
JP4618958B2 (ja) 生物学的エレメントの改変
KR20190034171A (ko) 아데노바이러스 단백질 vi 유래 펩티드를 포함하는 세포 내 전달용 조성물 및 이를 포함하는 항암용 약제학적 조성물
CA2527721A1 (en) Chimeric adenovirus capsid proteins
AU2004200869A1 (en) Cationic complexes of polymer-modified adenovirus
US20240240203A1 (en) Adenoviral vectors and vaccines thereof
KR100964802B1 (ko) 표면 변형 바이러스
CN117561070A (zh) 腺病毒载体及其疫苗
AU9140801A (en) Adenoviral vectors with modified tropism

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)